Here’s a polished English translation of the Chinese title: **”Fujifilm Life Sciences Debuts at Pharma Future Summit, Discussing Industrialization of In Vivo CAR-T and Stem Cell Therapies”**

ShanghaiJune 5, 2026 /PRNewswire/ — On June 4, 2026, the Pharma Future Summit was grandly held in Suzhou, bringing together top experts and innovative companies in the field of cell and gene therapy (CGT). Fujifilm, as a leading upstream raw material and solution supplier, was invited to participate and hosted a dedicated forum under the theme “In Vivo CAR-T and Stem Cell Therapy: R&D Breakthroughs and Industrialization Exploration,” collaborating with industry innovators such as Nanjing GenScript Biotech, Suzhou Zuo Xuan Xing Biotech, and Suzhou Xue Ji Biotech to explore cutting-edge CGT technologies and practical applications.

As the cell and gene therapy (CGT) industry accelerates toward large-scale production, achieving efficient, stable, and economically viable manufacturing has become a key focus. Fujifilm Life Science Application Scientist Huang Xin delivered a keynote speech titled “From Batch Culture to Perfusion: BalanCD HEK293 Ushering in a High-Yield Era for Gene Therapy,” systematically elaborating on the process optimization and commercial application of the BalanCD HEK293 series media in viral vector production. Addressing the core industry needs of “cost reduction, yield improvement, and quality enhancement” in gene therapy, the presentation showcased Fujifilm’s innovative technological strengths in the cell culture media field.

Subsequently, representatives from participating companies delivered insightful presentations on topics including global market opportunities and integrated solutions for in vivo CAR-T therapy, tLNP platform design and manufacturing, and platelet drug development derived from stem cell differentiation. During the roundtable discussion, participants engaged in in-depth exchanges on hot topics such as breakthroughs in CGT for treating major diseases, quality and regulatory challenges in industrialization, raw material selection criteria, and upstream and downstream collaborative innovation.

Fujifilm’s life science business encompasses product lines including cell culture media, cytokines, iPS-derived cells, and research reagents, committed to providing high-quality, end-to-end products and services for cutting-edge fields such as cell therapy, gene therapy, and antibody drugs. Its flagship products, including the BalanCD HEK293 series media and iCell iPS-derived cells, have been widely applied in gene therapy, vaccines, and antibody drugs, helping partners achieve efficient and stable process development and industrial-scale production.

Looking ahead, Fujifilm Life Science will continue to uphold the Group’s mission of “contributing to a world with more smiles,” partnering with industry peers to provide solutions addressing key pain points, accelerate the implementation of cutting-edge therapies like CGT, and empower the high-quality development of the biopharmaceutical industry in China and globally.